Clinical Report: Renal Cell Carcinoma Associated with KIF5B-ALK Rearrangement

Overview

This report details a rare case of renal cell carcinoma (RCC) with a KIF5B-ALK gene fusion in a 39-year-old male, highlighting the critical role of molecular characterization in diagnosing ALK-RCC, which is challenging due to its rarity and potential treatment implications.

Background

ALK-rearranged renal cell carcinoma (ALK-RCC) is a newly recognized subtype of RCC, accounting for approximately 0.3% of cases. The identification of ALK fusions, including KIF5B-ALK, is crucial for accurate diagnosis and potential targeted therapy, which may significantly impact patient outcomes. Understanding the molecular characteristics of ALK-RCC can enhance clinical management and treatment options for affected patients.

Data Highlights

Key Findings

• ALK-RCC is characterized by the fusion of the ALK gene with various partner genes, including KIF5B.
• The case presented involved a 39-year-old male with a left renal tumor measuring 2.8 × 2.7 × 2.6 cm.
• Histopathological examination revealed atypical morphology consistent with renal epithelial differentiation, including specific cellular features.
• Next-generation sequencing confirmed the presence of a KIF5B-ALK gene fusion.
• ALK-RCC poses challenges in management due to its rarity and limited treatment options.
• Targeted therapies directed at the ALK gene may be beneficial for patients with ALK-RCC.

Clinical Implications

Clinicians should consider molecular testing for ALK fusions, such as KIF5B-ALK, in atypical cases of renal cell carcinoma. The identification of these fusions may guide targeted therapy options, improving patient outcomes in this rare subtype of RCC.

Conclusion

This case highlights the significance of molecular characterization in renal cell carcinoma and the potential for targeted therapies in managing ALK-RCC. Further research, including clinical trials, is needed to establish effective treatment protocols.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- C5orf46: a promising prognosis risk indicator with implication in the remodeling of KIRC and pan-cancer tumor microenvironments
2. Frontiers in Immunology, 2026 -- Case Report: ALK-positive histiocytosis with a novel PTRH2::ALK fusion masquerading as a liver abscess in an infant
3. Frontiers in Oncology, 2026 -- Case Report: Recurrent uterine inflammatory myofibroblastic tumor harboring IGFBP5-ALK fusion with sustained response to iruplinalkib
4. Blood Cancer Journal, 2016 -- Crizotinib Efficacy in Treating Refractory Pediatric Acute Myeloid Leukemia Associated with RAN-Binding Protein 2-ALK Fusion Gene
5. WHO 2022 Renal Cell Tumor Classification: Imaging Features and Clinical Implications | RadioGraphics
6. EAU Guidelines on Renal Cell Carcinoma 2026
7. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial | npj Precision Oncology
8. WHO 2022 Renal Cell Tumor Classification: Imaging Features and Clinical Implications | RadioGraphics
9. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2026.pdf
10. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial | npj Precision Oncology